This inhibitor activates the NOTCH pathway, inhibiting, consequently, the transcription factor achaete–scute complex-like 1 (ASCL1), with this ultimately leading to tumorigenesis repression and to the reversion of the neuroendocrine phenotype in this type of tumour. This evidence concerns the gene ASCL1 and neoplasm.